Martin Shkreli, an infamous drug company executive known as the “Pharma Bro,” has been moved to solitary confinement and ultimately removed from a minimum security environment at the Fort Dix federal prison in New Jersey.
His alleged new crime: Shkreli reportedly smuggled in a cell phone and was using it to run his drug business, Phoenixus AG.
Shkreli is in the midst of serving a seven-year prison sentence after being indicted on several investor fraud-related charges in 2017.
He’s now being detained at the Metropolitan Detention Center in Brooklyn, New York.
Shkreli’s lawyer, Benjamin Brafman, said that his client will be detained there for the time being. Then, Shkreli will be transferred to another federal prison in Allenwood, Pennsylvania.
According to the Wall Street Journal, Shkreli spirited a cellphone into Fort Dix and was using it to direct operations at Phoenixus AG.
Shkreli was reportedly rendering decisions on R&D initiatives and even tried to get the company’s CEO fired, though unsuccessfully.
Shkreli earned heaps of public scorn in 2015 when his company, Turing Pharmaceuticals, increased the price of a drug beyond the financial reach of those who desperately needed it.
In 2015, Turing Pharmaceuticals increased the price of one of its drugs, Daraprim, from $13.50 a pill to over $750 a pill, a price increase of over 5,000%.
Daraprim treats parasitic infections in babies, small children, HIV patients, and pregnant women.
Although Shkreli’s company was hardly the only one to engage in such practices, Shkreli differentiated himself by publicly defending and rejoicing in such strategies.
This business decision, and Shkreli’s subsequent public gloating about it, was the beginning of his downfall.
The scandal precipitated the PR need to rebrand Turing into Phoenixus. Shkreli’s public behavior also immediately attracted the attention of federal law enforcement.
In 2017, Shkreli was found guilty of three out of eight federal charges. He was sentenced to seven years in prison in 2018.
The most serious charges included defrauded his investors and then stealing money from another drug company he founded, Retrophin, to pay back his defrauded investors.
Small-cap winners galoreThe big stock market winners share one common attribute: Near the beginning of the ascent of their shares, the companies offer revolutionary products or services, are market leaders in their respective industries, or both. Some big stock market winners that possessed the attributes outlined above are Netflix (NFLX), which we recommended to investors in October 2002; Intuitive Surgical (ISRG), which we bought and recommended in July 2004; Baidu.com (BIDU), which we bought and recommended in August 2006; and MercadoLibre (MELI), which we recommended to investors in October 2010. Get up-to-date small-cap stock picks from David Frazier, editor of Small-Cap Profit Confidential.
Smarter cryptocurrency investmentsThe stock market crash of 2008 was the catalyst for his journey into alternatives. And interestingly, it was the impetus behind the creation of Bitcoin and the blockchain technology behind it. Keene Little wasn’t ready to risk his money yet but he was very curious, so he began charting Bitcoin’s technical patterns. What finally convinced him to dip a toe into digital currencies was seeing that they followed familiar price patterns that could be analyzed and successfully acted on. Now he shares those insights with subscribers to the Crypto Wealth Protocol.